GNTA Genenta Science S.p.A. Company Assets

GNTA (genenta.com) - company brandmark

This chart of total assets for Genenta Science S.p.A. (GNTA) on the GURU.Markets platform captured a value of 26.40. The business relies on proprietary interferon delivery to the brain, creating a potential barrier to entry for competitors. Genenta Science S.p.A. (GNTA) aims to capture the oncology market by expanding the application of Temferon vectors, although high development costs and regulatory uncertainty present significant financial challenges.

GNTA - Genenta Company Total Assets over the range 07/04/2022 - 10/29/2026

Analytical breakdowns and data insights for company genenta.com (GNTA)

- market value and analyst target forecast:
Stock Price Genenta Science|GNTA - Price Target Chart
- market capitalization data:
Market Value Genenta Science S.p.A.|GNTA - Total Company Value
- balance sheet equity data:
Equity per Share Genenta Science|GNTA - Book Capitalization|Market Cap to Net Assets Ratio genenta.com|GNTA - Aggregate Company Assets
- debt and liquidity details:
Debt to Capital Genenta Science S.p.A.|GNTA - Long-Term Debt to Equity|Short-Term Debt to Equity Genenta Science|GNTA - Company Debts|Debts to Book Value Genenta Science S.p.A.|GNTA - Company Long-Term Debts|Short-Term Indebtedness Genenta Science|Immediate Liquidity genenta.com
- earnings and market ratios statistics:
GNTA - Net Income
Basic company analysis:GNTA Genenta
Signature product of Genenta Science

To objectively assess the issuer, it is essential to track the total resource volume, which in this case is reverse-calculated via ROA and amounts to 26.40. The trend in gross assets reflects a business expansion vector, which for the pre-revenue company Genenta Science (GNTA) signifies the accumulation of capital to protect patents for lentiviral interferon delivery until the completion of critical clinical trial stages.

Direct competitors

legendbiotech.com (LEGN) - Company Total Assets|Aggregate Company Assets Sana Biotechnology, Inc.|Company Assets Autolus Therapeutics PLC AUTL|Aggregate Company Assets Allogene Therapeutics Inc (ALLO)|Selecta Biosciences Inc. - Total Business Assets|Company Total Assets CLLS (Cellectis)|CRBU - Cumulative Company Assets|TIL - Aggregate Company Assets|Company Assets Century Therapeutics|jaspertherapeutics.com (JSPR) - Aggregate Company Assets|SNTI (Senti Biosciences) - Aggregate Company Assets|Aggregate Company Assets Adaptimmune Therapeutics plc|Company Assets CERo Therapeutics Holdings Inc. CERO|Company Total Assets TCRT|achillestx.com (ACHL) - Company Balance Sheet Assets|Cargo Therapeutics - Cumulative Company Assets|Poseida Corp (PSTX) - Company Assets|TSVT: Cumulative Company Assets|Aggregate Asset Value GRCL (gracellbio.com)